Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study

Expert Opinion on Drug Delivery

Volumn 14, Issue 2, 2017, Pages 165-177

  Arora, Rhythm ^a   Katiyar, Sameer S ^a   Kushwah, Varun ^a   Jain, Sanyog ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

calcipotriol; Cyclosporine; HaCaT cell line; imiquimod induced psoriatic model; NLC; SLN

Indexed keywords

CALCIPOTRIOL; CARBOPOL 934; CYCLOSPORIN; IMIQUIMOD; INTERLEUKIN 6; LIPID; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR; DRUG CARRIER; NANOMATERIAL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; EX VIVO STUDY; GEL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PSORIASIS; SKIN PENETRATION; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; MEDICINAL CHEMISTRY; METABOLISM; SKIN; SKIN ABSORPTION;

ANIMALS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; LIPIDS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NANOSTRUCTURES; PARTICLE SIZE; PSORIASIS; SKIN; SKIN ABSORPTION;

EID: 85001976365     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1080/17425247.2017.1264386     Document Type: Article

References (50)

1. Chandra A, Ray A, Senapati S, et al. Genetic and epigenetic basis of psoriasis pathogenesis. Mol Immunol. 2015;64:313–323.
2. Griffiths CEM, Barker JNWN., Pathogenesis and clinical features of psoriasis. The Lancet. 2007;370:263–271.
3. Lin Y-K, Huang Z-R, Zhuo R-Z, et al. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine. 2010;5:117–128.
4. Kim ST, Jang D-J, Kim JH, et al. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation. Int J Pharm Sci. 2009;64:510–514.• The article provides information about CsA delivery consideration as a single moiety in SLN.
5. Austad J, Bjerke JR, Gjertsen BT, et al. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Drmatol Enereol. 1998;11:19–24.• Annotated articles help to understand combination therapy advantage with CT.
6. Chaturvedi SP, Kumar V. A review on disease management and drug delivery aspects in psoriasis. Curr Trends Technol Sci. 2012;1:122–125.
7. Rahman M, Akhter S, Ahmad J, et al. Nanomedicine-based drug targeting for psoriasis:potentials and emerging trends in nanoscale pharmacotherapy. Exp Opin Drug Deliv. 2015;12:635–652.
8. Souto E, Doktorovova S, Boonme P, et al. Lipid-based colloidal systems (nanoparticles, microemulsions) for drug delivery to the skin:materials and end-product formulations. J Drug Deliv Sci Technol. 2011;21:43–54.
9. Müller RH, Radtke M, Wissing SA, et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131–S55.
10. Zhang Z, Tsai P-C, Ramezanli T, et al. Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5:205–218.
11. Thapa RK, Yoo BK. Evaluation of the effect of tacrolimus-loaded liquid crystalline nanoparticles on psoriasis-like skin inflammation. J Dermatol Treat. 2014;25:22–25.
12. Bessar H, Venditti I, Benassi L, et al. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids Surf B Biointerfaces. 2016;141:141–147.
13. Pinto MF, Moura CC, Nunes C, et al. A new topical formulation for psoriasis:development of methotrexate-loaded nanostructured lipid carriers. Int J Pharm. 2014;477:519–526.
14. Kokelj F, Torsello P, Plozzer C, et al. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 1998;10:143–146.
15. Zhou L, Yang L, Tilton S, et al. Development of a high throughput equilibrium solubility assay using miniaturized shake‐flask method in early drug discovery. J Pharm Sci. 2007;96:3052–3071.• The reference provides quick view about utilization of shake flask method for determination of drug solubility.
16. Ranpise NS, Korabu SS, Ghodake VN, et al. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf B Biointerfaces. 2014;116:81–87.
17. Shete H, Patravale V. Long chain lipid based tamoxifen NLC. Part I:Preformulation studies, formulation development and physicochemical characterization. Int J Pharm. 2013;454:573–583.
18. Griffin WC. Classification of surface-active agents by” HLB”. J Soc Cosmetic Chemists. 1946;1:311–326.
19. Keck CM, Baisaeng N, Durand P, et al. Oil-enriched, ultra-small nanostructured lipid carriers (usNLC):a novel delivery system based on flip–flop structure. Int J of Pharm. 2014;477:227–235.
20. Pardeike J, Weber S, Haber T, et al. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm. 2011;419:329–338.• Relatively simple method for the preparation of NLC is reported in the referred article.
21. Mukherjee S, Ray S, Thakur R, et al. Solid lipid nanoparticles:a modern formulation approach in drug delivery system. Ind J Pharm Sci. 2009;71:349.
22. Jain S, Mittal A, K Jain A, et al. Enhanced topical delivery of cyclosporin-A using PLGA nanoparticles as carrier. Curr Nanosci. 2011;7:524–530.
23. Chen J, Chen H, Cui S, et al. Glucosamine derivative modified nanostructured lipid carriers for targeted tumor delivery. J Mater Chem. 2012;22:5770–5783.
24. Fry DW, White JC, Goldman ID, et al. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem. 1978;90:809–815.
25. Raza K, Singh B, Lohan S, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65–72.
26. Feng X, Tang Y, Duan X, et al. Lipid-modified conjugated polymer nanoparticles for cell imaging and transfection. J Mater Chem. 2010;20:1312–1316.
27. Harde H, Agrawal AK, Katariya M, et al. Development of a topical adapalene-solid lipid nanoparticle loaded gel with enhanced efficacy and improved skin tolerability. RSC Adv. 2015;5:43917–43929.
28. Harde H, Das M, Jain S, et al. Solid lipid nanoparticles:an oral bioavailability enhancer vehicle. Exp Opin Drug Deliv. 2011;8:1407–1424.
29. Jain S, Mistry MA, Swarnakar NK, et al. Enhanced dermal delivery of acyclovir using solid lipid nanoparticles. Drug Deliv Transl Res. 2011;1:395–406.
30. Baroli B, López-Quintela MA, Delgado-Charro MB, et al. Microemulsions for topical delivery of 8-methoxsalen. J Control Release. 2000;69:209–218.
31. Touitou E, Meidan VM, Horwitz E. Methods for quantitative determination of drug localized in the skin. J Control Release. 1998;56:7–21.
32. Surber C, Schwarb FP, Smith EW, et al. Tape-stripping technique. J Toxicol Cutan Ocul Toxicol. 2001;20:461–474.
33. Egbaria K, Weiner N. Liposomes as a topical drug delivery system. Adv Drug Deliv Rev. 1990;5:287–300.
34. Alvarez-Román R, Naik A, Kalia Y, et al. Skin penetration and distribution of polymeric nanoparticles. J Control Release. 2004;99:53–62.
35. Breitkreutz D, Boukamp P, Ryle CM, et al. Epidermal morphogenesis and keratin expression in c-Ha-ras-transfected tumorigenic clones of the human HaCaT cell line. Cancer Res. 1991;51:4402–4409.
36. Rückert R, Asadullah K, Seifert M, et al. Inhibition of keratinocyte apoptosis by IL-15:a new parameter in the pathogenesis of psoriasis? J Immunol. 2000;165:2240–2250.
37. Patil-Gadhe A, Kyadarkunte A, Patole M, et al. Montelukast-loaded nanostructured lipid carriers:part II pulmonary drug delivery and in vitro–in vivo aerosol performance. Eur Jpharmaceut Biopharmaceut. 2014;88:169–177.
38. Gokce EH, Korkmaz E, Dellera E, et al. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers:evaluation of antioxidant potential for dermal applications. Int J Nanomed. 2012;7:1841.•• Procedure for MTT assay is briefly depicted which gives considerable idea about the study.
39. Cao Y, Sun Z, Liao L, et al. Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun. 2005;332:370–379.
40. Koelsch C. Edible water vapor barriers:properties and promise. Trends Food Scitech. 1994;5:76–81.
41. Mehnert W, Mäder K. Solid lipid nanoparticles:production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
42. Schwarz C, Mehnert W, Lucks J, et al. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release. 1994;30:83–96.
43. Severino P, Andreani T, Macedo AS, et al. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv. 2011;2012.
44. Testerman T, Gerster J, Imbertson L, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol. 1995;58:365–372.
45. Jain AK, Thanki K, Jain S, et al. Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen:part I. Formulation development, statistical optimization, and in vitro characterization. Pharma Res. 2014;31:923–945.
46. Aungst BJ, Rogers NJ, Shefter E, et al. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int J Pharm. 1986;33:225–234.
47. Tan ES-T, Oon HH-B. Effective treatment of severe nail psoriasis using topical calcipotriol with betamethasone dipropionate gel. Indian J Dermatol Venereol Leprol. 2016;82:345.
48. Puglia C, Bonina F. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Exp Opin Drug Deliv. 2012;9:429–441.
49. Beutner KR, Tyring S. Human papillomavirus and human disease. ‎Am J Med. 1997;102:9–15.
50. Flutter B, Nestle FO. TLRs to cytokines:mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol. 2013;43:3138–3146.•• Impactful reference for the development of imiquimod-induced mouse model of psoriasis.